SELLAS Life Sciences Group Inc

NASDAQ:SLS   4:00:00 PM EDT
2.43
-0.09 (-3.57%)
: $2.70 +0.27 (+11.11%)
Products, Regulatory

Sellas Announces Data Showing Survival, Clinical Benefits Based On Phase 1/2 Clinical Trial Of Galinpepimut-S In Combination With Keytruda

Published: 11/10/2022 16:44 GMT
SELLAS Life Sciences Group Inc (SLS) - Sellas Announces Confirmatory Top-line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-s in Combination With Keytruda® (pembrolizumab) in Patients With Wt1+ Platinum-resistant Advanced Ovarian Cancer.
Sellas Life Sciences Group Inc - Clinical Benefit Observed in Patients Harboring Tumors With Detectable Pd-l1 Biomarker.
Sellas Life Sciences Group Inc - Full Clinical Trial Data to Be Presented at a Major Medical Conference in 1h 2023.
Sellas Life Sciences Group Inc - Median Overall Survival (os) Was 18.4 Months.
Sellas Life Sciences Group Inc - Median Progression-free Survival (pfs) Was 12 Weeks.
Sellas Life Sciences Group Inc - Orr of Trial is 6.3 Percent With a Disease Control Rate of 50.1 Percent at a Median Follow-up of 14.4 Months.
Sellas Life Sciences Group Inc - Safety Profile of Gps in Combination With Pembrolizumab Was Similar to Pembrolizumab Alone.